Unraveling Lyophilization and Redispersion Effects on Miktoarm Polymer-Based Nanoformulations.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Nanoparticles*/chemistry ; Polymers*/chemistry; Freeze Drying/methods ; Cryoprotective Agents/chemistry ; Humans ; Polyethylene Glycols/chemistry ; Drug Liberation ; Drug Compounding/methods ; Animals

To enhance the scope of therapeutic interventions using star polymeric nanoparticles of desired concentrations, an understanding of the effect of converting aqueous formulations into stable redispersible dry powders by freeze drying on their physicochemical and biological properties is essential. We demonstrate that parameters such as the choice of the cryoprotectant, its molecular weight, and concentration play an important role during lyophilization and reconstitution processes. We hypothesized that utilizing cryoprotectants akin to shell-forming polymers may be ideal in protection against aggregation and keeping the nanostructures intact during lyophilization and reconstitution, as well as retaining the overall biological efficacy of their cargo. Through an evaluation of miktoarm polymer-based nanoparticles, we demonstrate that PEG 2k at 1% w / v concentration provides the optimized cryoprotection, and the resulting solid formulations upon redispersion in an aqueous medium preserve the desired nanoparticle and curcumin properties. PEG 2k at 1% w / v is more efficient than PEG 5k and saccharides including glucose, sucrose, trehalose, and mannitol in enhancing the integrity of micelles during lyophilization and reconstitution. Addition of PEG 2k 1% w / v (with or without lyophilization and redispersion) enhances drug release in PBS buffer, while it has no impact in the cell culture media. Nanoformulations protect endothelial cells from cytotoxicity of curcumin, and addition of cryoprotectant or the lyophilization/redispersion processes did not impair anti-inflammatory efficacy of curcumin.

AAPS PharmSciTech. 2014 Feb;15(1):52-64. (PMID: 24092522)
Signal Transduct Target Ther. 2023 Nov 3;8(1):418. (PMID: 37919282)
Pharmaceutics. 2023 Jan 06;15(1):. (PMID: 36678829)
J Control Release. 2024 Nov;375:614-626. (PMID: 39316925)
J Control Release. 2017 Aug 10;259:105-114. (PMID: 28159516)
Biomacromolecules. 2011 Dec 12;12(12):4221-9. (PMID: 22047492)
Curr Drug Targets. 2018 Feb 19;19(4):339-359. (PMID: 27231107)
Front Pharmacol. 2021 Oct 04;12:735446. (PMID: 34675807)
Int J Mol Sci. 2022 Oct 03;23(19):. (PMID: 36233033)
Adv Drug Deliv Rev. 2022 Jan;180:114079. (PMID: 34902516)
J Biomed Mater Res A. 2008 May;85(2):539-46. (PMID: 17729259)
Int J Pharm. 2024 Nov 15;665:124696. (PMID: 39265853)
Angew Chem Int Ed Engl. 2014 May 12;53(20):5093-6. (PMID: 24700480)
Nat Commun. 2020 Nov 30;11(1):6089. (PMID: 33257670)
Signal Transduct Target Ther. 2018 Mar 16;3:7. (PMID: 29560283)
Biomacromolecules. 2023 Sep 11;24(9):4064-4077. (PMID: 37647594)
Pharmaceutics. 2020 Aug 30;12(9):. (PMID: 32872618)
Biomatter. 2012 Oct-Dec;2(4):329-39. (PMID: 23507897)
Pharmaceutics. 2020 Sep 19;12(9):. (PMID: 32961738)
Pharm Dev Technol. 2019 Jun;24(5):616-622. (PMID: 30477410)
Pharmaceutics. 2021 Aug 23;13(8):. (PMID: 34452283)
Cell Discov. 2023 Jan 23;9(1):9. (PMID: 36683074)
Antibiotics (Basel). 2023 Sep 04;12(9):. (PMID: 37760702)
J Transl Med. 2019 Mar 22;17(1):97. (PMID: 30902103)
AAPS J. 2010 Sep;12(3):263-71. (PMID: 20373062)
Eur J Pharm Sci. 2023 Oct 1;189:106557. (PMID: 37544333)
Colloids Surf B Biointerfaces. 2022 Sep;217:112702. (PMID: 35863234)
Biomaterials. 2007 Nov;28(31):4600-7. (PMID: 17675227)
Mol Pharm. 2017 Oct 2;14(10):3480-3488. (PMID: 28929769)
PLoS One. 2018 Jan 5;13(1):e0190713. (PMID: 29304068)
AAPS PharmSciTech. 2014 Dec;15(6):1498-508. (PMID: 25035070)
Front Pharmacol. 2024 Aug 26;15:1451634. (PMID: 39253381)
J Mater Chem B. 2024 Sep 25;12(37):9296-9311. (PMID: 39158840)
Nanomedicine (Lond). 2018 Jan;13(2):179-190. (PMID: 29139338)
Eur J Pharm Sci. 2024 Mar 1;194:106694. (PMID: 38191064)
RSC Med Chem. 2024 Jul 19;15(9):2980-2995. (PMID: 39309363)
Adv Mater. 2012 Jul 24;24(28):3823-30. (PMID: 22105885)
Eur J Pharm Sci. 2012 Aug 15;46(5):405-14. (PMID: 22465658)
J Control Release. 2016 Mar 10;225:75-86. (PMID: 26805517)
Eur J Pharm Biopharm. 2021 Aug;165:345-360. (PMID: 34052428)
Eur J Pharm Biopharm. 2009 Jun;72(2):428-37. (PMID: 19462479)
J Biol Eng. 2024 Jan 25;18(1):12. (PMID: 38273413)
Macromol Biosci. 2021 Feb;21(2):e2000305. (PMID: 33620748)
Molecules. 2021 Jul 01;26(13):. (PMID: 34279384)
Front Nutr. 2023 Jan 10;9:1040259. (PMID: 36712505)
Molecules. 2020 Aug 15;25(16):. (PMID: 32824172)
Biomater Sci. 2023 Jun 13;11(12):4327-4334. (PMID: 37073472)
Int J Mol Sci. 2022 May 10;23(10):. (PMID: 35628105)
Materials (Basel). 2023 Jan 31;16(3):. (PMID: 36770218)
J Mater Chem B. 2015 Mar 14;3(10):2043-2055. (PMID: 32262372)
J Pharm Sci. 2014 Sep;103(9):2950-2959. (PMID: 24585389)
Int J Nanomedicine. 2021 Feb 17;16:1313-1330. (PMID: 33628022)
Cancer Treat Res Commun. 2022;32:100605. (PMID: 35816909)
Pharmaceutics. 2023 Mar 13;15(3):. (PMID: 36986789)
Int J Nanomedicine. 2016 Aug 23;11:4093-106. (PMID: 27601897)
Drug Des Devel Ther. 2016 Mar 01;10:911-25. (PMID: 27041995)

Keywords: curcumin-loaded nanoformulations; drug delivery; lyophilization/redispersion; nanoformulations; polymeric nanoparticles

0 (Cryoprotective Agents)
3WJQ0SDW1A (Polyethylene Glycols)
0 (Polymers)

Date Created: 20251029 Date Completed: 20251029 Latest Revision: 20251101

20251101

PMC12563623

10.3390/ijms262010015

41155308